Advertisement

Topics

Onxeo S.A. Company Profile

11:27 EST 16th December 2018 | BioPortfolio

Onxeo has the vision to become a global leader and pioneer in oncology, with a focus on orphan or rare cancers, through developing innovative therapeutic alternatives to “make the difference”. The Onxeo teams are determined to develop innovative medicines to provide patients with hope and significantly improve their lives.


News Articles [19 Associated News Articles listed on BioPortfolio]

Summary of Onxeo's Liquidity Contract with CM-CIC Securities

Regulatory News: Pursuant to the liquidity contract granted to CM-CIC SECURITIES regarding Onxeo (Paris:ONXEO) (NASDAQ OMX:ONXEO) shares, the following resources were listed in the liquidity accou...

Onxeo to Attend Key Investor and Partnering Conferences in the Coming Months

Regulatory News: Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO FR0010095596), a clinical-stage biotechnology company specializing in the development of innovative drugs in oncology, today a...

Onxeo: Publication of the 2018 Half-Yearly Financial Report

Regulatory News: Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO FR0010095596), a clinical-stage biotechnology company specializing in the development of innovative drugs in oncology, in part...

Onxeo Reports Decision from the Paris Court of Appeal in the Lawsuit against SpeBio/SpePharm

Regulatory News: Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), a clinical-stage biotechnology company specializing in the development of innovative drugs in oncology targeting tumor DNA D...

Onxeo to Present Overview of AsiDNA for Treatment of Solid Tumors at DNA Damage Response Therapeutics Summit 2019

Regulatory News: Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO FR0010095596), a clinical-stage biotechnology company specializing in the development of innovative drugs in oncology, targeti...

Onxeo: Summary of the End of the Liquidity Contract with CM-CIC Securities and Implementation of a New Liquidity Contract with Kepler Cheuvreux

Regulatory News: Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), a clinical-stage biotechnology company specializing in the development of innovative drugs in oncology targeting tumor DNA D...

Onxeo (ONXEO) - Green light for Ph Ib/II after DRIIV-1 interim data

Edison Investment Research - Pharmaceutical & healthcare - Onxeo: Onxeo’s lead asset, AsiDNA, is currently being tested in a Phase I DRIIV-1 trial in patients with advanced solid tumours (n=36)....

Deals and M&As this week: Alliance Pharma, Bayer, Onxeo

Alliance Pharma plans to acquire exclusive distribution rights to Nizoral, an anti-dandruff brand, from Janssen Pharmaceutica NV for £60m ($79.5m). Alliance...Read More... The post Deals and M&...

Drugs and Medications [0 Results]

None

PubMed Articles [0 Results]

None

Clinical Trials [0 Results]

None

Companies [2 Associated Companies listed on BioPortfolio]

Onxeo S.A.

Onxeo has the vision to become a global leader and pioneer in oncology, with a focus on orphan or rare cancers, through developing innovative therapeutic alternatives to “mak...

Onxeo SA

Onxeo has the vision to become a global leader and pioneer in oncology, with a focus on orphan or rare cancers, through developing innovative therapeutic alternatives to “mak...

More Information about "Onxeo S.A." on BioPortfolio

We have published hundreds of Onxeo S.A. news stories on BioPortfolio along with dozens of Onxeo S.A. Clinical Trials and PubMed Articles about Onxeo S.A. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Onxeo S.A. Companies in our database. You can also find out about relevant Onxeo S.A. Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...


Corporate Database Quicklinks



Searches Linking to this Company Record